Developing TherapiesTo Transform Lives
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients.
Innovative Therapies
Our investigational therapies target rare diseases through three modalities: gene replacement, exon skipping gene therapy and vectorized RNA knockdown.
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients.
Innovative Therapies
Our investigational therapies target rare diseases through three modalities: gene replacement, exon skipping gene therapy and vectorized RNA knockdown.
Employees: 201-500
Total raised: $337.5M
Founded date: 2012
Investors 7
| Date | Name | Website |
| - | Asset Mana... | assetman.c... |
| - | Aisling Ca... | aislingcap... |
| - | 5AM Ventur... | 5amventure... |
| - | Foresite C... | foresiteca... |
| - | Hercules C... | htgc.com |
| - | RA Capital... | racap.com |
| - | Sofinnova ... | sofinnova.... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 25.01.2018 | - | $200M | - |
| 13.10.2015 | Series C | $65M | - |
| 02.12.2014 | Series B | $42.5M | - |
| 18.07.2013 | Series A | $30M | - |
Mentions in press and media 15
| Date | Title | Description |
| 28.06.2020 | Two patients die in Audentes gene therapy study, heightening concerns over high-dose treatments | Two patients in a study of a high-dose gene therapy for a rare muscle disorder have died, heightening worries about the safety of potent treatments under development for other diseases. Audentes Therapeutics, a San Francisco-based unit of t... |
| 26.08.2016 | Sofinnova Ventures has raised $595M for its largest fund to date | The company’s strategy of investing in late-stage private companies has found some receptive buyers for those businesses, demonstrated by acquisitions of its portfolio companies from the likes of Teva, Shire and Pfizer. And yet, it has also... |
| 04.01.2016 | Biotech Startups Hit the Ground Running, With Six Filing IPO Plans Today | If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, which was the worst year for tech IPOs in particular since 2009. Even still, it came as a bit of a surprise today when not one or three but ... |
| 13.10.2015 | Audentes Therapeutics Closes $65M Series C Financing | Audentes Therapeutics, Inc., a San Francisco, CA-based biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, closed a $65m Series C financing. The round w... |
| 13.10.2015 | Daily funding roundup - October 13, 2015 | EverString raised $65M; Audentes Therapeutics bagged $65M; SteelBrick received $48M Predictive marketing company EverString has raised $65 million, in what is the largest round ever for an AI company. Lightspeed Venture Partners led the Com... |
| 13.10.2015 | Gene therapy player Audentes Therapeutics raises $65M | The round was led by existing investor Sofinnova Ventures and new investor Redmiel Group. Other participants include RA Capital Management, OrbiMed, 5AM Ventures, Versant Ventures, Deerfield Management and Venrock. [Photo credit: Freedigita... |
| 04.12.2014 | West Coast Biotech Roundup: Amgen, Ariosa, Avanir, Audentes & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Where is biotech innovation? All over, we would contend, but according to The Scientist magazine, San Diego has been an especially good place to look this year. The publicatio... |
| 02.12.2014 | Audentes Therapeutics Closes $42.5M Series B Financing | Audentes Therapeutics, Inc., a San Francisco, CA-based biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, closed a $42.5m Series B financing. The round... |
| 02.12.2014 | AUDENTES THERAPEUTICS RAISES $42.5 MILLION IN SERIES B FINANCING | - |
| 18.10.2013 | Health IT deals help push software deals to 12-year high but life science struggles | Here were the biggest health IT deals for the quarter based on data from the MoneyTree Report and Mercom Capital Group’s Healthcare IT report. Evolent Health raised $100 million. EHR provider Practice Fusion raised $70 million. MedSynergies... |
Show more